Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To look at the prognostic value of new biomarkers in CSF and serum for characterisation of multiple sclerosis
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Analysis of cerebrospinal fluid and serum | Other | Analysis of biomarkers in patient biological samples |
| Measure | Description | Time Frame |
|---|---|---|
| Level of tumour necrosis factor receptor in cerebrospinal fluid | ELISA | Baseline |
| Level of Neurofilament in cerebrospinal fluid | ELISA | Baseline |
| Level of GFAP in cerebrospinal fluid | ELISA | Baseline |
| Level of secreted glycoprotein in cerebrospinal fluid | ELISA | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Level of tumour necrosis factor receptor in serum | ELISA | Baseline |
| Level of Neurofilament in serum | ELISA | Baseline |
Not provided
Inclusion criteria
Not provided
Not provided
Not provided
Not provided
Patients from whom prospective samples have been collected and conserved in the biobank at Nice as part of the RISC (Radiologically Isolated Syndrome Consortium).
100 patients with Radiologically Isolated Syndrome as diagnosed by MRI using the Okuda 2009 criteria (65 RIS-: not converted after at least 2 years of follow-up; 35 RIS+).
30 patients with recurrent-remittent multiple sclerosis 30 symptomatic control patients 20 control patients with inflammatory disease 20 control patients with non-inflammatory neurological disease
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Eric Thouvenot | CHU Nimes | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU Nimes | Nîmes | 30029 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29564952 | Result | Thouvenot E, Hinsinger G, Demattei C, Uygunoglu U, Castelnovo G, Pittion-Vouyovitch S, Okuda D, Kantarci O, Pelletier D, Lehmann S, Marin P, Siva A, Lebrun C. Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome. Mult Scler. 2019 Apr;25(5):669-677. doi: 10.1177/1352458518767043. Epub 2018 Mar 22. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood and cerebrospinal fluid
| Level of GFAP in serum | ELISA | Baseline |
| Level of secreted glycoprotein in serum | ELISA | Baseline |
| Comparison of the conversion time according to the threshold value of each biomarker for Radiologically Isolated Syndrome patients | Log-rank test | Baseline |
| Compare prognostic value of all four markers of the high risk criteria (age below 37, male, myelitis). | Multivariate analysis | Baseline |
| Biomarker levels in CSF and serum in different patient subpopulations (Radiologically Isolated Syndrome, recurrent remittent MS, symptomatic controls, central nervous system inflammatory disease controls, non-inflammatory disease controls) | Baseline |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |